Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
However, as of 2023, lixisenatide is no longer available as a standalone agent in the USA
In 2024 Wegovy was the first drug approved by the FDA to treat cardiovascular disease in people with obesity
Aug 2007;50(8):1211-1214
Healio: How will these results inform patients care going forward
This may happen because of certain stomach or bowel conditions, previous surgery, pernicious anaemia or other medical reasons
Phase 3 (remaining TRIUMPH, TRANSCEND, SYNERGY trials): Results expected throughout 2026
US$ 23.13
US$ 23.10
US$ 22.17
US$ 24.41
US$ 29.54
US$ 23.55
US$ 25.68
